Back to mobile site

BWS Financial Downgrades SciClone Pharmaceuticals (SCLN) to Hold; SEC Investigation Overhang

August 10, 2010 8:55 AM EDT Send to a Friend
BWS Financial downgrades SciClone Pharmaceuticals (Nasdaq: SCLN) from Buy to Hold.

BWS analyst says, "What was a positive earnings report ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login